Author:
Kappos Ludwig,Radue Ernst-Wilhelm,Chin Peter,Ritter Shannon,Tomic Davorka,Lublin Fred
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Reference19 articles.
1. Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170
2. Calabresi P, Radue E, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556
3. Chun J, Brinkmann V (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12:213–228
4. Cohen J, Pelletier J, Chin P et al (2013) Efficacy of fingolimod in RRMS as measured by multiple sclerosis functional composite: results from the TRANSFORMS, FREEDOMS, and FREEDOMS II phase 3 studies. Mult Scler 19:268
5. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415